Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Oncolytics Biotech (ONCY) Reports Q3 Loss of $0.16
November 11, 2020 4:52 PM ESTOncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.16), versus ($0.16) reported last year.
Financial Highlights
As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million during the third quarter through the issuing of common stock through our ATM facility.Operating expense for the third quarter of 2020 was $2.5 million, compared to $1.8 million in the third quarter of 2019.R&D expense for the third quarter of 2020 was $3.9 million, compared to $1.7 million in the third quarter of 2019.Net cash used in operating activities for the third... More